查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1813988

肝癌診斷市場規模、佔有率和趨勢分析報告：按測試類型、最終用途、地區和細分市場預測，2025-2033 年

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type, By End-use, By Region And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肝癌診斷市場摘要

預計 2024 年全球肝癌診斷市場價值將達到 99.9 億美元，到 2033 年將達到 175.7 億美元，2025 年至 2033 年的複合年成長率為 6.42%。

肝癌是全球所有致命疾病中死亡的主要原因。

自1980年以來，肝癌發生率增加了兩倍，死亡率則加倍。美國癌症協會估計，2025年將有約42,240例新病例和30,090例死亡病例。因此，全球肝癌盛行率的上升，加上持續存在的危險因素，可能會顯著加速篩檢和診斷市場的成長。肝癌發生率的上升推動了對早期癌症診斷的需求，並促使人們努力降低相關危險因子。早期發現，尤其是透過有效的篩檢項目，對於減少癌症相關死亡至關重要。總體而言，與延遲發現相比，早期診斷癌症可以將患者存活率提高五到十倍。

隨著全球肝癌患者數量的增加，對早期檢測工具和篩檢方法的需求也日益成長。例如，2025 年 4 月，美國國家癌症研究所建立了肝細胞癌篩檢(PDQ) - 醫療保健專業版計劃，該計劃利用細針抽吸細胞學檢查和經子宮頸肝切片檢查等技術。該計劃重點關注高風險族群，例如患有慢性肝病的人，提高對超音波、 電腦斷層掃描和血液檢查等診斷工具的認知和使用。早期和定期篩檢可提高檢出率和患者預後。對預防和早期診斷的日益重視正在推動肝癌診斷的技術創新並加速市場成長。

由於尖端早期篩檢技術的不斷發展，肝癌篩檢和治療正在發生重大轉變。這些新的技術創新為肝癌診斷市場的成長鋪平了道路。例如，2025 年 4 月，FDA 授予 EvoLiver切片檢查測試突破性醫療設備稱號，用於監測肝硬化高風險患者的肝細胞癌 (HCC)。此測試使用基於細胞外囊泡 (EV) 的多體學學生物標記特徵，在檢測早期 HCC 方面顯示出良好的結果。來自包括 464 個患者檢體的 MEV01 試驗的數據顯示，EvoLiver 測試在檢測早期 HCC 方面實現了令人印象深刻的 86% 的敏感性和 88% 的特異性。這些結果明顯優於超音波和甲胎蛋白檢測等目前的監測方法。這種創新方法有可能顯著改善肝硬化患者的 HCC 管理。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章肝癌診斷市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場前景。
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 肝癌診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章肝癌診斷市場：測試類型估計和趨勢分析

  • 細分儀表板
  • 肝癌診斷市場：產品差異分析
  • 肝癌診斷市場規模及趨勢分析（依檢測類型，2021-2033）
    • 2021-2033年全球臨床檢測市場
    • 影像學
    • 內視鏡檢查
    • 切片檢查

第5章肝癌診斷市場：最終用途估計與趨勢分析

  • 2024年和2033年的最終用途市場佔有率
  • 細分儀表板
  • 全球肝癌診斷市場：依最終用途分類的展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 醫院和診斷實驗室
    • 2021-2033年全球醫院與診斷實驗室市場
  • 學術和研究機構
    • 2021-2033年全球學術與研究機構市場
  • 製藥/CRO實驗室
    • 2021-2033年全球製藥和CRO實驗室市場

第6章肝癌診斷市場：區域估計與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 市場規模、預測趨勢分析，2021-2033年：
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Qiagen NV
    • Siemens Healthineers
    • Becton, Dickinson &Company
    • Illumina, Inc.
    • Epigenomics AG
    • Koninklijke Philips NV
    • Fujifilm Medical Systems USA, Inc.
Product Code: GVR-3-68038-012-5

Liver Cancer Diagnostics Market Summary

The global liver cancer diagnostics market size was estimated at USD 9.99 billion in 2024 and is projected to reach USD 17.57 billion by 2033, growing at a CAGR of 6.42% from 2025 to 2033. Liver cancer is the leading cause of death amongst all deadly diseases in the globe.

Since 1980, the rate of incidence of liver cancer has tripled and death rates have doubled during this period. The American Cancer Society estimated that in 2025, about 42,240 new cases are expected, and about 30,090 people will succumb to death. Thus, the global rise in liver cancer prevalence, combined with ongoing exposure to risk factors, will significantly accelerate the growth of the screening and diagnosis market. The rising incidence of liver cancer is increasing the demand for early-stage cancer diagnosis and efforts to reduce associated risk factors. Early detection is crucial in lowering cancer-related deaths, especially through effective screening programs. Overall, diagnosing cancer early can boost patient survival rates by 5 to 10 times compared to later detection.

As the global cases of liver cancer grow, the need for early detection tools and screening methods has intensified. For instance, the National Cancer Institute established the Liver (Hepatocellular) Cancer Screening (PDQ)-health professional version program in April 2025, utilizing techniques like needle aspiration cytology and trans jugular liver biopsy. Programs focused on high-risk groups, such as those with chronic liver conditions, are promoting greater awareness and use of diagnostic tools like ultrasound, CT scans, and blood tests. Early and regular screenings improve detection rates and patient outcomes. This increased emphasis on prevention and early diagnosis is driving innovations in liver cancer diagnostics and accelerating market growth.

Liver cancer screening and treatment are poised for a major shift thanks to cutting-edge early screening technologies currently in advanced development stages. These new innovations are paving the way for growth in the liver diagnostics market. For instance, in April 2025, the FDA granted breakthrough device designation to the EvoLiver biopsy test for monitoring hepatocellular carcinoma (HCC) in patients with high-risk cirrhosis. The test uses a multiomics biomarker signature based on extracellular vesicles (EV) and has shown promising results in detecting early-stage HCC. Data from the MEV01 trial, which involved 464 patient samples, indicated that the EvoLiver test achieved an impressive 86% sensitivity and 88% specificity for early-stage HCC detection. These results significantly surpass current surveillance methods like ultrasound and alpha-fetoprotein testing. This innovative approach has the potential to improve the management of hepatocellular carcinoma in cirrhotic patients greatly.

Global Liver Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global liver cancer diagnostics market report on the basis of test type, end-use, and region:

  • Test type Outlook (Revenue, USD Million, 2021 - 2033)
  • Laboratory Tests
    • Biomarkers
    • Oncofetal and Glycoprotein Antigens
    • Enzymes and Isoenzymes
    • Growth Factors and Receptors
    • Molecular Markers
    • Pathological Biomarkers
    • Blood Tests
  • Imaging
  • Endoscopy
  • Biopsy
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & CRO Laboratories
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Incidence of Liver Cancer
      • 3.2.1.2. Technological Advancements
      • 3.2.1.3. Extensive R&D For Developing Novel Testing Solutions
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic imaging
  • 3.3. Liver Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Liver Cancer Diagnostics Market: Test type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Cancer Diagnostics Market: Product Movement Analysis
  • 4.3. Liver Cancer Diagnostics Market Size & Trend Analysis, by test type, 2021 to 2033 (USD Million)
    • 4.3.1. Global Laboratory Tests Market, 2021 - 2033 (USD MILLION)
      • 4.3.1.1. Biomarkers
        • 4.3.1.1.1. Global biomarkers market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.1. Oncofetal and Glycoprotein Antigens
            • 4.3.1.1.1.1.1. Global oncofetal and glycoprotein antigens market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.2. Enzymes and Isoenzymes
            • 4.3.1.1.1.2.1. Global enzymes and isoenzymes market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.3. Growth Factors and Receptors
            • 4.3.1.1.1.3.1. Global growth factors and receptors market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.4. Molecular Markers
            • 4.3.1.1.1.4.1. Global molecular markers market, 2021 - 2033 (USD million)
          • 4.3.1.1.1.5. Pathological Biomarkers
            • 4.3.1.1.1.5.1. Global pathological biomarkers market, 2021 - 2033 (USD million)
      • 4.3.1.2. Blood Tests
        • 4.3.1.2.1. Global blood tests market, 2021 - 2033 (USD million)
    • 4.3.2. Imaging
      • 4.3.2.1. Global Imaging Market, 2021 - 2033 (USD MILLION)
    • 4.3.3. Endoscopy
      • 4.3.3.1. Global Endoscopy Market, 2021 - 2033 (USD MILLION)
    • 4.3.4. Biopsy
      • 4.3.4.1. Global Biopsy Market, 2021 - 2033 (USD MILLION)

Chapter 5. Liver Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Liver Cancer Diagnostics Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Hospitals & Diagnostic Laboratories
    • 5.5.1. Global Hospitals & Diagnostic Laboratories market, 2021 - 2033 (USD Million)
  • 5.6. Academic & Research Institutes
    • 5.6.1. Global Academic & Research Institutes Market, 2021 - 2033 (USD million)
  • 5.7. Pharmaceutical & CRO Laboratories
    • 5.7.1. Global Pharmaceutical & CRO Laboratories market, 2021 - 2033 (USD million)

Chapter 6. Liver Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 6.5. North America
    • 6.5.1. North America: SWOT Analysis
    • 6.5.2. U.S.
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/Reimbursement
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/Reimbursement
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/Reimbursement
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe: SWOT Analysis
    • 6.6.2. UK
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/Reimbursement
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/Reimbursement
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/Reimbursement
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/Reimbursement
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/Reimbursement
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/Reimbursement
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/Reimbursement
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key country dynamics
      • 6.6.9.2. Regulatory framework/Reimbursement
      • 6.6.9.3. Competitive scenario
      • 6.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Asia Pacific: SWOT Analysis
    • 6.7.2. Japan
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/Reimbursement
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.3. China
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/Reimbursement
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.4. India
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/Reimbursement
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.5. Australia
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/Reimbursement
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.6. South Korea
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/Reimbursement
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.7. Thailand
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Regulatory framework/Reimbursement
      • 6.7.7.3. Competitive scenario
      • 6.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Latin America: SWOT Analysis
    • 6.8.2. Brazil
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/Reimbursement
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/Reimbursement
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. MEA: SWOT Analysis
    • 6.9.2. South Africa
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/Reimbursement
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.3. Saudi Arabia
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/Reimbursement
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.4. UAE
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/Reimbursement
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.5. Kuwait
      • 6.9.5.1. Key country dynamics
      • 6.9.5.2. Regulatory framework
      • 6.9.5.3. Competitive scenario
      • 6.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. Abbott Laboratories
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Services benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Thermo Fisher Scientific, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Services benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. F. Hoffmann-La Roche Ltd.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Services benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Qiagen N.V.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Services benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Siemens Healthineers
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Services benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Becton, Dickinson & Company
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Services benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Illumina, Inc.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Services benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Epigenomics AG
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Services benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Koninklijke Philips N.V.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Services benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Fujifilm Medical Systems U.S.A., Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Services benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Liver cancer diagnostics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 4 North America Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 5 U.S Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 6 U.S Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 7 Canada Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 8 Canada Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Mexico Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 10 Mexico Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Europe Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 12 Europe Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 13 UK Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 14 UK Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Germany Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 16 Germany Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 17 France Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 18 France Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Italy Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 20 Italy Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 21 Spain Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 22 Spain Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 23 Denmark Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 24 Denmark Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 25 Sweden Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 26 Sweden Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 27 Norway Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 28 Norway Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 29 Asia Pacific Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 30 Asia Pacific Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 31 Japan Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 32 Japan Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 33 China Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 34 China Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 35 India Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 36 India Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Australia Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 38 Australia Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 39 South Korea Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 40 South Korea Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Thailand Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 42 Thailand Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Latin America Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 44 Latin America Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Brazil Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 46 Brazil Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Argentina Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 48 Argentina Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 49 MEA Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 50 MEA Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 51 South Africa Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 52 South Africa Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 53 Saudi Arabia Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 54 Saudi Arabia Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 55 UAE Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 56 UAE Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Kuwait Liver cancer diagnostics market, by test type, 2021 - 2033 (USD Million)
  • Table 58 Kuwait Liver cancer diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Liver cancer diagnostics market: market outlook
  • Fig. 14 Liver cancer diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Liver cancer diagnostics market driver impact
  • Fig. 20 Liver cancer diagnostics market restraint impact
  • Fig. 21 Liver cancer diagnostics market strategic initiatives analysis
  • Fig. 22 Liver cancer diagnostics market: Test type movement analysis
  • Fig. 23 Liver cancer diagnostics market: Test type outlook and key takeaways
  • Fig. 24 Laboratory Tests Liver Cancer Diagnostics market estimates and forecast, 2021 - 2033
  • Fig. 25 Imaging Liver Cancer Diagnostics estimates and forecast, 2021 - 2033
  • Fig. 26 Endoscopy Liver Cancer Diagnostics market estimates and forecast, 2021 - 2033
  • Fig. 27 Biopsy Liver Cancer Diagnostics market estimates and forecast, 2021 - 2033
  • Fig. 28 Others Liver Cancer Diagnostics market estimates and forecast, 2021 - 2033
  • Fig. 29 Liver cancer diagnostics market: End Use movement analysis
  • Fig. 30 Liver cancer diagnostics market: End Use outlook and key takeaways
  • Fig. 31 Hospitals & Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 32 Academic and Research Institutes market estimates and forecasts, 2021 - 2033
  • Fig. 33 Pharmaceutical & CRO Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 34 Global Liver cancer diagnostics market: Regional movement analysis
  • Fig. 35 Global Liver cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 36 Global Liver cancer diagnostics market share and leading players
  • Fig. 37 North America market share and leading players
  • Fig. 38 Europe market share and leading players
  • Fig. 39 Asia Pacific market share and leading players
  • Fig. 40 Latin America market share and leading players
  • Fig. 41 Middle East & Africa market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecasts, 2021 - 2033
  • Fig. 45 U.S.
  • Fig. 46 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 47 Canada
  • Fig. 48 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 49 Mexico
  • Fig. 50 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecasts, 2021 - 2033
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 57 France
  • Fig. 58 France market estimates and forecasts, 2021 - 2033
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 65 Sweden
  • Fig. 66 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 67 Norway
  • Fig. 68 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 71 China
  • Fig. 72 China market estimates and forecasts, 2021 - 2033
  • Fig. 73 Japan
  • Fig. 74 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 75 India
  • Fig. 76 India market estimates and forecasts, 2021 - 2033
  • Fig. 77 Thailand
  • Fig. 78 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 79 South Korea
  • Fig. 80 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 81 Australia
  • Fig. 82 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 85 Brazil
  • Fig. 86 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 87 Argentina
  • Fig. 88 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 89 Middle East and Africa
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 91 South Africa
  • Fig. 92 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 93 Saudi Arabia
  • Fig. 94 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 95 UAE
  • Fig. 96 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 97 Kuwait
  • Fig. 98 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 99 Market share of key market players- Liver cancer diagnostics market